Equities

Orgenesis Inc

Orgenesis Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.52
  • Today's Change-0.010 / -1.92%
  • Shares traded14.53k
  • 1 Year change-50.94%
  • Beta1.2075
Data delayed at least 15 minutes, as of May 08 2024 20:59 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Orgenesis Inc. is a biotech company focused on cell and gene therapies (CGTs). The Company focuses on the development of autologous therapies that can be manufactured under processes and systems that are developed for each therapy using a closed and automated approach that is validated for compliant production near the patient for treatment of the patient at the point of care. It operates in two segments: Octomera LLC (Octomera segment) and therapies related activities (Therapies segment). The Octomera segment includes mainly point of care (POCare) services. The Therapies segment includes the Company’s therapeutic development operations. The POCare Services platform is utilized by parties, such as biotech companies and hospitals for the supply of their products. Octomera’s services include adapting the process to the platform and supplying the products; adaptation of automation and closed systems to serviced therapies, and contract research organization services for clinical trials.

  • Revenue in USD (TTM)530.00k
  • Net income in USD-55.36m
  • Incorporated2008
  • Employees146.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Biotricity Inc11.63m-15.39m11.31m55.00------0.9727-1.75-1.751.32-2.841.922.016.55211,408.70-240.40-303.46----65.5253.00-125.43-368.780.1012-0.5855----26.00--35.36------
ALR Technologies Inc9.49k-8.00m12.02m6.00------1,266.27-0.0147-0.01470.00002-0.04760.0358----1,581.67-3,015.28-12,861.64----62.49---84,283.24-406,011.30---0.8626---------42.72------
PetVivo Holdings Inc1.05m-10.63m12.49m25.00--12.41--11.94-0.8694-0.86940.08420.060.33751.212.0441,841.60-343.12-209.90-715.73-504.6451.4120.27-1,016.55-2,297.210.6169-2,268.840.1392--693.46260.32-73.83--51.73--
STRATA Skin Sciences Inc33.36m-10.83m13.68m99.00--1.08--0.41-0.3101-0.31010.95530.36190.70765.177.49336,949.50-22.97-11.48-31.53-16.5555.3461.28-32.47-17.701.06-4.430.5425---7.752.24-95.17--23.29--
BioSig Technologies Inc18.00k-29.05m14.22m4.00------790.09-4.08-4.080.0025-0.32220.00610.001.094,500.00-971.23-269.73---363.1172.22---159,388.90-24,485.730.1152-------93.71---6.52---9.58--
REMSleep Holdings Inc203.73k-1.78m16.08m6.00--17.42--78.92-0.0012-0.00120.00010.00060.08921.6619.66---77.85-152.40-92.09-317.98-371.44---872.65-2,317.523.18-353.980.00---36.48--12.13--28.26--
QT Imaging Holdings Inc0.00-4.02m17.10m----0.7866-----0.3999-0.39990.001.010.00-------12.32---16.60--------------0.3042-------45.07------
Dalrada Financial Corporation31.32m-22.48m17.17m0.00------0.5483-0.2547-0.25470.3552-0.03341.229.255.22---90.33-80.63-513.68--25.0139.23-74.24-63.940.6296-25.241.61--54.35---43.94------
Orgenesis Inc530.00k-55.36m17.88m146.00------33.73-1.97-1.970.0184-0.65830.0181.230.02923,630.14-123.09---313.24---1,080.19---12,248.68--0.2464-16.1816.82---98.53-50.94-271.82---17.71--
Agape ATP Corp1.43m-2.10m18.13m21.00--4.15--12.67-0.0276-0.02760.01890.05680.335310.5028.0968,147.14-49.44---68.03--65.44---147.44--4.79--0.0179---22.92---24.61------
Meihua International Medical Tech Co Ltd97.10m11.63m18.15m617.001.470.11661.500.18690.48560.48564.066.110.578846.661.31157,372.606.9112.268.1315.0534.1938.1411.9415.475.21--0.04750.00-6.055.1086.22-5.56-9.16--
PAVmed Inc2.45m-66.27m20.75m107.00------8.46-9.24-9.240.3392-6.280.0563--62.8722,915.89-182.01-154.56---1,152.82-161.87---3,232.63-8,764.890.447-10.582.19--550.40--25.76--55.51--
Neuraxis Inc2.46m-14.63m20.77m17.00------8.44-3.78-3.780.5432------------------87.67---594.57-----23.75-----8.37---163.78------
Ekso Bionics Holdings Inc17.91m-14.24m25.08m70.00--1.78--1.40-0.9685-0.96851.200.77650.54231.653.38255,900.00-43.11-43.63-57.86-57.6750.4151.93-79.48-104.242.11-34.630.2937--41.5710.03-0.7825--3.69--
SANUWAVE Health Inc20.40m-25.81m25.09m31.00------1.23-0.0455-0.04550.0257-0.03790.96473.165.56657,967.80-122.05-136.54----70.4169.13-126.52-189.600.1055-0.0214----21.8461.61-150.72------
Data as of May 08 2024. Currency figures normalised to Orgenesis Inc's reporting currency: US Dollar USD

Institutional shareholders

6.31%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 31 Dec 2023914.46k2.68%
Knoll Capital Management LPas of 31 Dec 2023634.74k1.86%
Geode Capital Management LLCas of 31 Dec 2023239.26k0.70%
BlackRock Fund Advisorsas of 31 Dec 2023122.81k0.36%
SSgA Funds Management, Inc.as of 31 Dec 202388.66k0.26%
Northern Trust Investments, Inc.(Investment Management)as of 31 Dec 202339.12k0.12%
Renaissance Technologies LLCas of 31 Dec 202338.80k0.11%
Peilim Portfolio Management Co. Ltd.as of 31 Mar 202432.05k0.09%
Redwood Financial Network Corp.as of 31 Mar 202425.00k0.07%
Chapin Davis, Inc. (Investment Management)as of 31 Mar 202420.00k0.06%
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.